Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Promoting colonoscopy screening among low-income Latinos at average risk of colorectal cancer: A randomized clinical trial.

DuHamel KN, Schofield EA, Villagra C, Sriphanlop P, Itzkowitz SH, Cotter G, Cohen N, Erwin DO, Winkel G, Thompson HS, Zauber AG, Jandorf LH.

Cancer. 2019 Nov 19. doi: 10.1002/cncr.32541. [Epub ahead of print]

PMID:
31742670
2.

Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population.

Lee JK, Jensen CD, Levin TR, Doubeni CA, Zauber AG, Chubak J, Kamineni AS, Schottinger JE, Ghai NR, Udaltsova N, Zhao WK, Fireman BH, Quesenberry CP, Orav EJ, Skinner CS, Halm EA, Corley DA.

Gastroenterology. 2019 Oct 4. pii: S0016-5085(19)41411-X. doi: 10.1053/j.gastro.2019.09.039. [Epub ahead of print]

PMID:
31589872
3.

High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis.

Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, Zauber AG, Knudsen AB, Ladabaum U.

Ann Intern Med. 2019 Sep 24. doi: 10.7326/M18-3633. [Epub ahead of print]

PMID:
31546257
4.

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.

Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM, Lansdorp-Vogelaar I.

PLoS One. 2019 Sep 4;14(9):e0220234. doi: 10.1371/journal.pone.0220234. eCollection 2019.

5.

Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.

Barlow WE, Beaber EF, Geller BM, Kamineni A, Zheng Y, Haas JS, Chao CR, Rutter CM, Zauber AG, Sprague BL, Halm EA, Weaver DL, Chubak J, Doria-Rose VP, Kobrin S, Onega T, Quinn VP, Schapira MM, Tosteson ANA, Corley DA, Skinner CS, Schnall MD, Armstrong K, Wheeler CM, Silverberg MJ, Balasubramanian BA, Doubeni CA, McLerran D, Tiro JA.

J Natl Cancer Inst. 2019 Jul 11. pii: djz137. doi: 10.1093/jnci/djz137. [Epub ahead of print]

PMID:
31292633
6.

A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer.

Dwyer AJ, Murphy CC, Boland CR, Garcia R, Hampel H, Limburg P, Lowery J, Zauber AG, Waring S, Worrall S, Perea J, Siegel R, Lee J, Molmenti C, Sears CL, Buckhaults P, Hayes R, Hussan H, de Miranda N, Palles C, Diaz L, Song M, Cercek A, Lieu CH, Patel SG, Karlitz JJ, Cao Y, Demb J, Blatchford P, Risendal B, Weltzien E, Wali A, Daschner P, Loomans-Kropp H, Flores R, Levell CL, Wehling K, Martin J, Pesmen C, Kuchar V, Soisson R, Davis A, Ahnen D.

Gastroenterology. 2019 Aug;157(2):280-288. doi: 10.1053/j.gastro.2019.04.049. Epub 2019 May 13. No abstract available.

PMID:
31095950
7.

Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings.

Lee JK, Jensen CD, Levin TR, Zauber AG, Schottinger JE, Quinn VP, Udaltsova N, Zhao WK, Fireman BH, Quesenberry CP, Doubeni CA, Corley DA.

JAMA Intern Med. 2019 Feb 1;179(2):153-160. doi: 10.1001/jamainternmed.2018.5565.

PMID:
30556824
8.

Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems.

Chubak J, McLerran D, Zheng Y, Singal AG, Corley DA, Doria-Rose VP, Doubeni CA, Kamineni A, Haas JS, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF; PROSPR consortium.

Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):91-98. doi: 10.1158/1055-9965.EPI-18-0452. Epub 2018 Nov 20.

PMID:
30459208
9.

Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women.

Liu PH, Wu K, Ng K, Zauber AG, Nguyen LH, Song M, He X, Fuchs CS, Ogino S, Willett WC, Chan AT, Giovannucci EL, Cao Y.

JAMA Oncol. 2019 Jan 1;5(1):37-44. doi: 10.1001/jamaoncol.2018.4280.

10.

Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death.

Doubeni CA, Fedewa SA, Levin TR, Jensen CD, Saia C, Zebrowski AM, Quinn VP, Rendle KA, Zauber AG, Becerra-Culqui TA, Mehta SJ, Fletcher RH, Schottinger J, Corley DA.

Gastroenterology. 2019 Jan;156(1):63-74.e6. doi: 10.1053/j.gastro.2018.09.040. Epub 2018 Sep 27.

PMID:
30268788
11.

Colorectal Cancer Screening Participation Among Asian Americans Overall and Subgroups in an Integrated Health Care Setting with Organized Screening.

Ghai NR, Jensen CD, Corley DA, Doubeni CA, Schottinger JE, Zauber AG, Lee AT, Contreras R, Levin TR, Lee JK, Quinn VP.

Clin Transl Gastroenterol. 2018 Sep 21;9(9):186. doi: 10.1038/s41424-018-0051-2.

12.

Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers.

Tollivoro TA, Jensen CD, Marks AR, Zhao WK, Schottinger JE, Quinn VP, Ghai NR, Zauber AG, Doubeni CA, Levin TR, Fireman B, Quesenberry CP, Corley DA.

Gastrointest Endosc. 2019 Jan;89(1):168-176.e3. doi: 10.1016/j.gie.2018.08.023. Epub 2018 Aug 23.

PMID:
30144415
13.

Health supervision for people with Bloom syndrome.

Cunniff C, Djavid AR, Carrubba S, Cohen B, Ellis NA, Levy CF, Jeong S, Lederman HM, Vogiatzi M, Walsh MF, Zauber AG.

Am J Med Genet A. 2018 Sep;176(9):1872-1881. doi: 10.1002/ajmg.a.40374. Epub 2018 Jul 28.

PMID:
30055079
14.

Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population.

Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG, Lee JK, Zhao WK, Udaltsova N, Ghai NR, Lee AT, Quesenberry CP, Fireman BH, Doubeni CA.

Gastroenterology. 2018 Nov;155(5):1383-1391.e5. doi: 10.1053/j.gastro.2018.07.017. Epub 2018 Jul 19.

15.

Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.

Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, Dwyer A, Ahnen DJ, Siegel RL, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2974-2985. doi: 10.1002/cncr.31542. Epub 2018 May 30.

16.

The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.

Peterse EFP, Meester RGS, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2964-2973. doi: 10.1002/cncr.31543. Epub 2018 May 30.

17.

Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH.

Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM.

Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):728-736. doi: 10.1158/1055-9965.EPI-17-0573. Epub 2018 May 16.

18.

Reply.

Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB.

Gastroenterology. 2018 Jun;154(8):2283-2284. doi: 10.1053/j.gastro.2018.05.017. Epub 2018 May 8. No abstract available.

PMID:
29750906
19.

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.

Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB; Cystic Fibrosis Colorectal Cancer Screening Task Force.

Gastroenterology. 2018 Feb;154(3):736-745.e14. doi: 10.1053/j.gastro.2017.12.012. Epub 2017 Dec 29.

PMID:
29289528
20.

Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.

Gastroenterology. 2017 Dec 27. pii: S0016-5085(17)36715-X. doi: 10.1053/j.gastro.2017.12.011. [Epub ahead of print]

PMID:
29288655
21.

Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I.

Health Aff (Millwood). 2017 Dec;36(12):2151-2159. doi: 10.1377/hlthaff.2017.0228.

22.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

23.

Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Feb;154(3):556-567.e18. doi: 10.1053/j.gastro.2017.10.036. Epub 2017 Nov 2.

24.

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review.

Selby K, Baumgartner C, Levin TR, Doubeni CA, Zauber AG, Schottinger J, Jensen CD, Lee JK, Corley DA.

Ann Intern Med. 2017 Oct 17;167(8):565-575. doi: 10.7326/M17-1361. Epub 2017 Oct 10. Review.

25.

A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.

Shapiro JA, Bobo JK, Church TR, Rex DK, Chovnick G, Thompson TD, Zauber AG, Lieberman D, Levin TR, Joseph DA, Nadel MR.

Am J Gastroenterol. 2017 Nov;112(11):1728-1735. doi: 10.1038/ajg.2017.285. Epub 2017 Oct 10.

26.

Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer.

Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KAB, Zallen DT, Ganiats TG, Webber EM, Janssens ACJW, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Gastroenterology. 2018 Jan;154(1):105-116.e20. doi: 10.1053/j.gastro.2017.09.021. Epub 2017 Sep 28.

27.

Accurate Identification of Colonoscopy Quality and Polyp Findings Using Natural Language Processing.

Lee JK, Jensen CD, Levin TR, Zauber AG, Doubeni CA, Zhao WK, Corley DA.

J Clin Gastroenterol. 2019 Jan;53(1):e25-e30. doi: 10.1097/MCG.0000000000000929.

PMID:
28906424
28.

Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer.

Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I.

Int J Cancer. 2017 Dec 1;141(11):2359-2367. doi: 10.1002/ijc.30933. Epub 2017 Aug 31.

29.

Can post-polypectomy surveillance be less intensive?

Winawer SJ, Zauber AG.

Lancet Oncol. 2017 Jun;18(6):707-709. doi: 10.1016/S1470-2045(17)30305-4. Epub 2017 Apr 28. No abstract available.

30.

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Schottinger JE, Marks AR, Zhao WK, Ghai NR, Lee AT, Contreras R, Quesenberry CP, Fireman BH, Levin TR.

JAMA. 2017 Apr 25;317(16):1631-1641. doi: 10.1001/jama.2017.3634.

31.

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study.

Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15. No abstract available.

32.

Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy.

McFerran E, O'Mahony JF, Fallis R, McVicar D, Zauber AG, Kee F.

Epidemiol Rev. 2017 Jan 1;39(1):148-160. doi: 10.1093/epirev/mxx002. Review.

33.

Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.

Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, Yong JH, Kroep S, Tinmouth J, Lansdorp-Vogelaar I.

PLoS One. 2017 Mar 15;12(3):e0172864. doi: 10.1371/journal.pone.0172864. eCollection 2017.

34.

Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Doubeni CA, Jensen CD, Fedewa SA, Quinn VP, Zauber AG, Schottinger JE, Corley DA, Levin TR.

J Am Board Fam Med. 2016 Nov 12;29(6):672-681. doi: 10.3122/jabfm.2016.06.160060.

35.

Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.

Marcus PM, Pashayan N, Church TR, Doria-Rose VP, Gould MK, Hubbard RA, Marrone M, Miglioretti DL, Pharoah PD, Pinsky PF, Rendle KA, Robbins HA, Roberts MC, Rolland B, Schiffman M, Tiro JA, Zauber AG, Winn DM, Khoury MJ.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1449-1455. Epub 2016 Aug 9.

36.

Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study.

Doubeni CA, Corley DA, Quinn VP, Jensen CD, Zauber AG, Goodman M, Johnson JR, Mehta SJ, Becerra TA, Zhao WK, Schottinger J, Doria-Rose VP, Levin TR, Weiss NS, Fletcher RH.

Gut. 2018 Feb;67(2):291-298. doi: 10.1136/gutjnl-2016-312712. Epub 2016 Oct 12.

37.

Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.

Mehta SJ, Jensen CD, Quinn VP, Schottinger JE, Zauber AG, Meester R, Laiyemo AO, Fedewa S, Goodman M, Fletcher RH, Levin TR, Corley DA, Doubeni CA.

J Gen Intern Med. 2016 Nov;31(11):1323-1330. doi: 10.1007/s11606-016-3792-1. Epub 2016 Jul 13.

38.

Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting.

Lee A, Jensen CD, Marks AR, Zhao WK, Doubeni CA, Zauber AG, Quinn VP, Levin TR, Corley DA.

Gastrointest Endosc. 2017 Mar;85(3):601-610.e2. doi: 10.1016/j.gie.2016.09.033. Epub 2016 Oct 1.

39.

Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.

Beaber EF, Tosteson AN, Haas JS, Onega T, Sprague BL, Weaver DL, McCarthy AM, Doubeni CA, Quinn VP, Skinner CS, Zauber AG, Barlow WE.

Breast Cancer Res Treat. 2016 Nov;160(2):323-331. Epub 2016 Sep 24.

40.

A restricted look at CRC screening: not considering annual stool testing as an option.

Kuntz KM, Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Berger BM, Levin B.

Am J Manag Care. 2016 Jul 1;22(7):e270-4. No abstract available.

41.

Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.

Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM.

JAMA. 2016 Jun 21;315(23):2595-609. doi: 10.1001/jama.2016.6828.

42.

Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state-of-the-science review.

Lowery JT, Ahnen DJ, Schroy PC 3rd, Hampel H, Baxter N, Boland CR, Burt RW, Butterly L, Doerr M, Doroshenk M, Feero WG, Henrikson N, Ladabaum U, Lieberman D, McFarland EG, Peterson SK, Raymond M, Samadder NJ, Syngal S, Weber TK, Zauber AG, Smith R.

Cancer. 2016 Sep 1;122(17):2633-45. doi: 10.1002/cncr.30080. Epub 2016 Jun 3. Review. Erratum in: Cancer. 2017 Oct 1;123(19):3857.

43.

Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial.

Bretthauer M, Kaminski MF, Løberg M, Zauber AG, Regula J, Kuipers EJ, Hernán MA, McFadden E, Sunde A, Kalager M, Dekker E, Lansdorp-Vogelaar I, Garborg K, Rupinski M, Spaander MC, Bugajski M, Høie O, Stefansson T, Hoff G, Adami HO; Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group.

JAMA Intern Med. 2016 Jul 1;176(7):894-902. doi: 10.1001/jamainternmed.2016.0960.

44.

Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.

Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1445-1451.e8. doi: 10.1016/j.cgh.2016.05.017. Epub 2016 May 19. Erratum in: Clin Gastroenterol Hepatol. 2018 May;16(5):787. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1365. Abstract corrected.

45.

Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity.

Joseph DA, Meester RG, Zauber AG, Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M.

Cancer. 2016 Aug 15;122(16):2479-86. doi: 10.1002/cncr.30070. Epub 2016 May 20. Erratum in: Cancer. 2017 Oct 1;123(19):3857.

46.

Rationale and design of the European Polyp Surveillance (EPoS) trials.

Jover R, Bretthauer M, Dekker E, Holme Ø, Kaminski MF, Løberg M, Zauber AG, Hernán MA, Lansdorp-Vogelaar I, Sunde A, McFadden E, Castells A, Regula J, Quintero E, Pellisé M, Senore C, Kalager M, Dinis-Ribeiro M, Emilsson L, Ransohoff DF, Hoff G, Adami HO.

Endoscopy. 2016 Jun;48(6):571-8. doi: 10.1055/s-0042-104116. Epub 2016 Apr 4.

47.

Colorectal Cancer Health Disparities and the Role of US Law and Health Policy.

Doubeni CA, Corley DA, Zauber AG.

Gastroenterology. 2016 May;150(5):1052-1055. doi: 10.1053/j.gastro.2016.03.012. Epub 2016 Mar 24. No abstract available.

48.

Colorectal Cancer.

Rabeneck L, Horton S, Zauber AG, Earle C.

In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, Third Edition (Volume 3). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2015 Nov 1. Chapter 6.

49.

Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.

Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, Zhao WK, Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN, Quesenberry CP, Levin TR, Mysliwiec PA.

Ann Intern Med. 2016 Apr 5;164(7):456-63. doi: 10.7326/M15-0983. Epub 2016 Jan 26.

50.

Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications.

Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I.

Med Decis Making. 2016 Jul;36(5):604-14. doi: 10.1177/0272989X15622642. Epub 2016 Jan 8.

Supplemental Content

Loading ...
Support Center